Lindita Vinca, APRN
Nurse Practitioner · Cheshire, CTNPI 1396093993
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $276,978 of the $427,308 with a category attached, or 64.8%. Johnson & Johnson accounts for 63.0% of it on its own, with 31 other manufacturers making up the rest. 2025 is the largest year on record at $196,673, more than ten times the $7,013 reported in 2021. Among nurse practitioner clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,654 payments — averaging $258.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$269K
- Sanofi$35K
- AbbVie$31K
- Incyte Corporation$17K
- Organon$15K
- Regeneron Healthcare Solutions, Inc.$15K
- plus $44K from 26 others
What the payments were for
- Consulting fees$42,13910%
- Speaking & faculty fees$276,97865%
- Travel & lodging$72,82217%
- Food & beverage$34,6338%
- Education$7360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 340 | $269,138 |
| Sanofi | 82 | $35,159 |
| AbbVie | 239 | $31,388 |
| Incyte Corporation | 96 | $17,442 |
| Organon | 35 | $14,996 |
| Regeneron Healthcare Solutions, Inc. | 86 | $14,762 |
| Arcutis Biotherapeutics, Inc. | 70 | $10,210 |
| Pfizer | 94 | $7,316 |
| Galderma Laboratories, L.p. | 52 | $6,849 |
| Medimetriks Pharmaceuticals, Inc. | 10 | $5,238 |
| Dermavant Sciences, Inc. | 85 | $2,461 |
| LEO Pharma Inc. | 57 | $1,590 |
| Almirall LLC | 30 | $1,475 |
| Novartis | 34 | $1,438 |
| Eli Lilly | 3 | $1,389 |
| Lilly USA, LLC | 61 | $1,184 |
| E.r. Squibb & Sons, L.L.C. | 55 | $1,106 |
| Sun Pharmaceutical Industries Inc. | 46 | $787 |
| Amgen | 38 | $708 |
| UCB, Inc. | 22 | $469 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 24 | $447 |
| EPI Health, LLC | 25 | $321 |
| VYNE Pharmaceuticals Inc. | 22 | $319 |
| Journey Medical Corporation | 11 | $307 |
| Mayne Pharma Commercial LLC | 17 | $295 |
| Boehringer Ingelheim | 9 | $175 |
| Janssen Scientific Affairs, LLC | 1 | $121 |
| Botanix SB Inc | 5 | $113 |
| Verrica Pharmaceuticals Inc. | 2 | $47 |
| LNHC, Inc | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Dermira, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tremfya$264,409
- DUPIXENT$46,349
- Skyrizi$26,257
- VTAMA$15,716
- ZORYVE$9,141
- OPZELURA$6,894
- SIMPONI ARIA$5,010
- CIBINQO$4,585
- Clindacin ETZ$2,988
- Neo-Synalar$2,488
- OLUMIANT$1,475
- EUCRISA$1,025
- Klisyri$1,000
- Rinvoq$900
- Neuac$500
- Tovet (emollient formulation)$250
- Sumadan Wash$250
- AMZEEQ$125
How this compares
$427,308 in reported general payments places this provider in the 95th percentile of 1,162 nurse practitioner providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 25 | $525,715 |
| TremfyaGuselkumab | 22 | $299,936 |
| Dupixent PenDupilumab | 58 | $273,515 |
| OtezlaApremilast | 23 | $111,643 |
| Clobetasol Propionate | 136 | $5,140 |
| Ivermectin | 13 | $3,082 |
| Metronidazole | 66 | $3,022 |
| Mometasone Furoate | 218 | $2,858 |
| Ketoconazole | 150 | $2,032 |
| Fluorouracil | 23 | $1,612 |
| Triamcinolone Acetonide | 129 | $1,406 |
| Minoxidil | 114 | $1,288 |
| Clindamycin Phosphate | 25 | $884 |
| Ciclopirox | 25 | $642 |
| Azelaic Acid | 17 | $562 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $269,138 | $299,93622 claims |
| AmgenOtezla | $708 | $111,64323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,162 nurse practitioner providers in Connecticut.
Other nurse practitioner in Cheshire
- Catherine MilnePlymouth$361K
- Michele NovellaDanbury$331K
- Tiffany RydzNewtown$49K
- Paul FidrychNorwich$23K
- Priscilla QuilterNorwich$21K
- Kimberly BoldonMiddletown$19K
- Emma RobinsonStamford$17K
- Janice TavaresBridgeport$17K
- Kelly WilberWaterbury$17K
- Suni JacobHamden$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.